Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Date of authorisation: 26/05/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Forsteo, teriparatide, Date of authorisation: 10/06/2003, Revision: 25, Status: Authorised

Handling competing interests

EMEA-001745-PIP01-14

EMEA-002572-PIP02-19-M05

Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Verzenios, abemaciclib, Date of authorisation: 26/09/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Optruma, raloxifene, Date of authorisation: 05/08/1998, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Date of authorisation: 13/02/2020, Revision: 17, Status: Authorised